Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AREENA SWARUP

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1508857301
CMS profile
340890
Location
MESA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,953.27

208 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,953.27 208

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AREENA SWARUP

NPI 1508857301 · CMS profile ID 340890

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

MESA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508857301?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AREENA SWARUP, NPI 1508857301, CMS profile ID 340890. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508857301?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). AREENA SWARUP, NPI 1508857301, CMS profile ID 340890. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508857301?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
AREENA SWARUP, NPI 1508857301, CMS profile ID 340890, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1508857301?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

208 matching records · $4,953.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 208 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 208.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $19.3609/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917884219 CMS
Amgen Inc. $11.3909/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809067 CMS
Lilly USA, LLC $24.1609/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917883817 CMS
Novartis Pharmaceuticals Corporation $22.3009/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894408201 CMS
ABBVIE INC. $27.2509/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482303 CMS
Novartis Pharmaceuticals Corporation $19.4009/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894408203 CMS
Amgen Inc. $21.2509/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939808985 CMS
UCB, Inc. $32.6809/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908111091 CMS
Amgen Inc. $16.3909/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933778715 CMS
GlaxoSmithKline, LLC. $16.3209/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945121089 CMS
Lilly USA, LLC $101.2309/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917884213 CMS
Amgen Inc. $6.9109/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809147 CMS
ABBVIE INC. $27.8709/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482301 CMS
Amgen Inc. $27.9409/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809063 CMS
Janssen Biotech, Inc. $16.0709/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885507141 CMS
PFIZER INC. $19.3309/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949333059 CMS
ABBVIE INC. $17.6909/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482299 CMS
Amgen Inc. $31.0209/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809143 CMS
ABBVIE INC. $20.7508/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482297 CMS
UCB, Inc. $26.6608/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908111083 CMS
PFIZER INC. $11.7708/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949226361 CMS
ABBVIE INC. $21.7708/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482295 CMS
Novartis Pharmaceuticals Corporation $20.7108/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894408197 CMS
Lilly USA, LLC $29.3208/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917883997 CMS
ABBVIE INC. $26.8508/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482293 CMS
Amgen Inc. $25.2408/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809139 CMS
Novartis Pharmaceuticals Corporation $20.9408/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894408199 CMS
ABBVIE INC. $27.9308/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482291 CMS
ABBVIE INC. $21.6308/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482289 CMS
Amgen Inc. $5.8508/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809135 CMS
Lilly USA, LLC $24.7908/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917883993 CMS
Alexion Pharmaceuticals, Inc. $15.9308/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920240349 CMS
Amgen Inc. $27.3008/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809059 CMS
Abbott Laboratories $105.7408/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914221050 CMS
Amgen Inc. $29.8608/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809131 CMS
UCB, Inc. $19.0508/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908111075 CMS
PFIZER INC. $23.3508/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949233773 CMS
ABBVIE INC. $26.2607/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482287 CMS
Amgen Inc. $24.5807/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809055 CMS
Genentech USA, Inc. $24.7007/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950695925 CMS
ABBVIE INC. $26.2707/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482285 CMS
PFIZER INC. $16.4607/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949212895 CMS
Amgen Inc. $28.3407/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809051 CMS
Novartis Pharmaceuticals Corporation $17.3307/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894408195 CMS
Lilly USA, LLC $26.0107/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917885737 CMS
Amgen Inc. $33.2907/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809127 CMS
Amgen Inc. $20.0507/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809047 CMS
Janssen Biotech, Inc. $19.1407/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885507153 CMS
ABBVIE INC. $25.5107/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892482283 CMS
PFIZER INC. $13.8007/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949209619 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,791.27 258
PY2020 $3,333.51 185
PY2021 $3,729.44 201
PY2022 $4,953.27 208
PY2023 $3,959.84 179
PY2024 $4,282.66 213
PY2025 $3,966.49 231

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $722,517.06 80
PY2024 Recipient $24,552.58 2
PY2024 Principal investigator $515,662.29 95
PY2023 Principal investigator $178,497.52 90
PY2022 Principal investigator $214,669.51 111
PY2021 Principal investigator $295,463.14 157
PY2020 Principal investigator $245,175.27 156
PY2019 Principal investigator $369,946.70 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $97.50 12/18/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202531238
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,776.72 12/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430674
Principal investigator 1 Novartis Pharmaceuticals Corporation $160,608.47 12/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES, PC
A Randomized, Controlled Study to Evaluate LNP023 (Iptacopan) in Patients With Active ANCA-associated Vasculitis No dispute reported 06/30/2026 1190312045
Principal investigator 1 ABBVIE INC. $1,369.83 12/04/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202527912
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $250.00 12/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430724
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,515.25 11/19/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430692
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $178.16 11/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430808
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,072.90 11/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430762
Principal investigator 1 SANOFI US SERVICES INC. $2,090.72 10/20/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083192
Principal investigator 1 ABBVIE INC. $97.50 10/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202517347
Principal investigator 1 ABBVIE INC. $1,369.83 10/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202515119
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $250.00 10/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430750
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $373.10 10/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430720
Principal investigator 1 UCB SA $323.70 09/29/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246656697
Principal investigator 1 Amgen Inc. $1,358.23 09/24/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH-S VINEYARD AVE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639327
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $269.96 09/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430806
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $55.90 08/20/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430688
Principal investigator 1 UCB SA $1,500.00 08/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658708
Principal investigator 1 UCB SA $1,200.00 08/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658710
Principal investigator 1 UCB SA $600.00 08/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658712
Principal investigator 1 UCB SA $464.00 08/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658716
Principal investigator 1 UCB SA $2,244.50 08/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659214
Principal investigator 1 UCB SA $928.00 08/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659216
Principal investigator 1 UCB SA $464.00 08/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659218
Principal investigator 1 UCB SA $464.00 08/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659220
Principal investigator 1 UCB SA $2,660.00 08/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659222
Principal investigator 1 ABBVIE INC. $35.00 07/31/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202500710
Principal investigator 1 Amgen Inc. $14,061.64 07/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246639279
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,517.23 07/23/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430672
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,500.70 07/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430748
Principal investigator 1 ABBVIE INC. $140.00 07/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202497964
Principal investigator 1 ABBVIE INC. $1,661.08 07/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202495705
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,079.46 06/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430682
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $174.56 06/20/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430804
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,804.40 06/11/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430734
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,482.00 05/19/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430676
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $250.00 05/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430736
Principal investigator 1 SANOFI US SERVICES INC. $600.00 04/14/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083132
Principal investigator 1 SANOFI US SERVICES INC. $600.00 04/14/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083135
Principal investigator 1 ABBVIE INC. $172.50 04/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202476060
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $250.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430726
Principal investigator 1 UCB SA $450.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658512
Principal investigator 1 UCB SA $20,391.80 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658514
Principal investigator 1 UCB SA $300.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658516
Principal investigator 1 UCB SA $202.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658518
Principal investigator 1 UCB SA $64.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658520
Principal investigator 1 UCB SA $64.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658522
Principal investigator 1 UCB SA $1,115.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658524
Principal investigator 1 UCB SA $64.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658526
Principal investigator 1 UCB SA $64.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658528
Principal investigator 1 UCB SA $1,611.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658530
Principal investigator 1 UCB SA $3,318.60 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658532
Principal investigator 1 UCB SA $2,227.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658534
Principal investigator 1 UCB SA $64.00 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658536
Principal investigator 1 ABBVIE INC. $1,369.83 04/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202474182
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,557.40 04/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430772
Principal investigator 1 Amgen Inc. $3,425.20 03/19/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH-S VINEYARD AVE
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246639323
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,943.85 03/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430756
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,983.80 03/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430704
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,804.40 03/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430698
Principal investigator 1 ABBVIE INC. $15,250.00 03/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202461782
Principal investigator 1 Novartis Pharmaceuticals Corporation $252,666.27 03/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES, PC
A Randomized, Controlled Study to Evaluate LNP023 (Iptacopan) in Patients With Active ANCA-associated Vasculitis No dispute reported 06/30/2026 1190303529
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,366.13 03/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430708
Principal investigator 1 Eli Lilly and Company $6,015.00 02/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
TALTZ PSA OBSERVATIONAL STUDY No dispute reported 06/30/2026 1187877143
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $16,208.40 02/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430718
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $28,870.70 01/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS RHEUMATOLOGY RESEARCH PLLC
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) No dispute reported 06/30/2026 1214123996
Principal investigator 1 Eli Lilly and Company $2,201.06 01/27/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187880151
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,517.23 01/27/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430776
Principal investigator 1 ABBVIE INC. $35.00 01/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202439461
Principal investigator 1 ABBVIE INC. $97.50 01/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202439465
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $30.23 01/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430782
Principal investigator 1 Janssen Research & Development, LLC $3,200.00 01/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1175396064
Principal investigator 1 Janssen Research & Development, LLC $3,406.00 01/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1175396133
Principal investigator 1 Janssen Research & Development, LLC $4,080.00 01/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1175396388
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $630.76 01/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430780
Principal investigator 1 Eli Lilly and Company $66,315.00 01/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187880725
Principal investigator 1 ABBVIE INC. $35.00 01/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202436437
Principal investigator 1 Eli Lilly and Company $40,824.35 01/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187880737
Principal investigator 1 ABBVIE INC. $1,369.83 01/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES PC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202435520
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $467.88 01/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430778